Literature DB >> 20651199

Screening patients to assess renal function before administering gadolinium chelates: assessment of the Choyke questionnaire.

Brena F Sena1, Julia P Stern, Pari V Pandharipande, Barbara Klemm, Julie Bulman, Ivan Pedrosa, Neil M Rofsky.   

Abstract

OBJECTIVE: The purpose of our study was to determine the efficacy of using the Choyke questionnaire to stratify the potential risk for nephrogenic systemic fibrosis (NSF) before a gadolinium-enhanced MRI examination and to compare the economic impact of such an approach with universal blood sampling before gadolinium-enhanced MRI.
MATERIALS AND METHODS: We retrospectively reviewed the records of 1,086 consecutive outpatients referred for gadolinium-enhanced MRI. For inclusion, patients were required to have an estimated glomerular filtration rate (eGFR) result within 30 days before gadolinium-enhanced MRI and a completed Choyke questionnaire, first when the order was placed and again at the point of service. Questionnaire results were dichotomized into "No" (all no responses in both questionnaires) or "Yes" (one or more yes responses in either questionnaire) response groups for comparison with the corresponding eGFR. An economic impact assessment for using the questionnaire to identify "at risk" patients was performed using a decision-analytic model.
RESULTS: Entry criteria were met in 665 of 1,086 (61.2%) patients. Zero patients in the No (n = 287) and seven in the Yes (1.9%) group (n = 378) had an eGFR of less than 30 mL/min/1.73 m(2). Using the 100% sensitivity achieved in identifying higher risk patients (seven patients; 95% CI, 59-100%), the questionnaire could save $4.52 per patient. At the lower boundary of the 95% CI for sensitivity, the savings incurred would come at the expense of administering gadolinium to 0.4% of patients with an eGFR less than 30 mL/min/1.73 m(2).
CONCLUSION: The Choyke questionnaire effectively stratifies patients for NSF risk before gadolinium-enhanced MRI, offering potential cost savings and streamlined care.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20651199      PMCID: PMC6247784          DOI: 10.2214/AJR.09.3803

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  18 in total

1.  Gadolinium--a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?

Authors:  Thomas Grobner
Journal:  Nephrol Dial Transplant       Date:  2006-01-23       Impact factor: 5.992

2.  Which study when? Is gadolinium-enhanced MR imaging safer than iodine-enhanced CT?

Authors:  Jeffrey C Weinreb
Journal:  Radiology       Date:  2008-10       Impact factor: 11.105

3.  Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging.

Authors:  Peter Marckmann; Lone Skov; Kristian Rossen; Anders Dupont; Mette Brimnes Damholt; James Goya Heaf; Henrik S Thomsen
Journal:  J Am Soc Nephrol       Date:  2006-08-02       Impact factor: 10.121

4.  Are screening serum creatinine levels necessary prior to outpatient CT examinations?

Authors:  R B Tippins; W E Torres; B R Baumgartner; D A Baumgarten
Journal:  Radiology       Date:  2000-08       Impact factor: 11.105

5.  A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group.

Authors:  A S Levey; J P Bosch; J B Lewis; T Greene; N Rogers; D Roth
Journal:  Ann Intern Med       Date:  1999-03-16       Impact factor: 25.391

6.  Identifying outpatients with renal insufficiency before contrast-enhanced CT by using estimated glomerular filtration rates versus serum creatinine levels.

Authors:  Brian R Herts; Erika Schneider; Emilio D Poggio; Nancy A Obuchowski; Mark E Baker
Journal:  Radiology       Date:  2008-05-05       Impact factor: 11.105

7.  Risk for nephrogenic systemic fibrosis with gadoteridol (ProHance) in patients who are on long-term hemodialysis.

Authors:  Robert F Reilly
Journal:  Clin J Am Soc Nephrol       Date:  2008-02-20       Impact factor: 8.237

8.  National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification.

Authors:  Andrew S Levey; Josef Coresh; Ethan Balk; Annamaria T Kausz; Adeera Levin; Michael W Steffes; Ronald J Hogg; Ronald D Perrone; Joseph Lau; Garabed Eknoyan
Journal:  Ann Intern Med       Date:  2003-07-15       Impact factor: 25.391

9.  High-dose gadodiamide for catheter angiography and CT in patients with varying degrees of renal insufficiency: Prevalence of subsequent nephrogenic systemic fibrosis and decline in renal function.

Authors:  Mellena D Bridges; Brandon S St Amant; Rebecca B McNeil; Joseph G Cernigliaro; Jamie P Dwyer; Peter M Fitzpatrick
Journal:  AJR Am J Roentgenol       Date:  2009-06       Impact factor: 3.959

10.  MR imaging in patients at risk for developing nephrogenic systemic fibrosis: protocols, practices, and imaging techniques to maximize patient safety.

Authors:  Krishna Juluru; Jens Vogel-Claussen; Katarzyna J Macura; Ihab R Kamel; Alexander Steever; David A Bluemke
Journal:  Radiographics       Date:  2008-11-19       Impact factor: 5.333

View more
  6 in total

Review 1.  Basic MR relaxation mechanisms and contrast agent design.

Authors:  Luis M De León-Rodríguez; André F Martins; Marco C Pinho; Neil M Rofsky; A Dean Sherry
Journal:  J Magn Reson Imaging       Date:  2015-05-14       Impact factor: 4.813

Review 2.  Renal imaging in patients with renal impairment.

Authors:  Jason A Poff; Elizabeth M Hecht; Parvati Ramchandani
Journal:  Curr Urol Rep       Date:  2011-02       Impact factor: 3.092

Review 3.  Nephrogenic systemic fibrosis and gadolinium-based contrast media: updated ESUR Contrast Medium Safety Committee guidelines.

Authors:  Henrik S Thomsen; Sameh K Morcos; Torsten Almén; Marie-France Bellin; Michele Bertolotto; Georg Bongartz; Olivier Clement; Peter Leander; Gertraud Heinz-Peer; Peter Reimer; Fulvio Stacul; Aart van der Molen; Judith A W Webb
Journal:  Eur Radiol       Date:  2012-08-04       Impact factor: 5.315

4.  Can a structured questionnaire identify patients with reduced renal function?

Authors:  Manal Azzouz; Janne Rømsing; Henrik S Thomsen
Journal:  Eur Radiol       Date:  2013-11-26       Impact factor: 5.315

5.  Concentration-dependent Early Antivascular and Antitumor Effects of Itraconazole in Non-Small Cell Lung Cancer.

Authors:  David E Gerber; William C Putnam; Farjana J Fattah; Kemp H Kernstine; Rolf A Brekken; Ivan Pedrosa; Rachael Skelton; Jessica M Saltarski; Robert E Lenkinski; Richard D Leff; Chul Ahn; Chyndhri Padmanabhan; Vaidehi Chembukar; Sahba Kasiri; Raja Reddy Kallem; Indhumathy Subramaniyan; Qing Yuan; Quyen N Do; Yin Xi; Scott I Reznik; Lorraine Pelosof; Brandon Faubert; Ralph J DeBerardinis; James Kim
Journal:  Clin Cancer Res       Date:  2020-08-26       Impact factor: 12.531

6.  Gadolinium-Based Contrast Agents in Kidney Disease: A Comprehensive Review and Clinical Practice Guideline Issued by the Canadian Association of Radiologists.

Authors:  Nicola Schieda; Jason I Blaichman; Andreu F Costa; Rafael Glikstein; Casey Hurrell; Matthew James; Pejman Jabehdar Maralani; Wael Shabana; An Tang; Anne Tsampalieros; Christian B van der Pol; Swapnil Hiremath
Journal:  Can J Kidney Health Dis       Date:  2018-06-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.